Literature DB >> 3524903

Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B.

S G Young, R S Smith, D M Hogle, L K Curtiss, J L Witztum.   

Abstract

We describe two new monoclonal antibody-based, solid-phase immunoenzymometric assays for the quantification of apolipoprotein (apo) B in plasma: a competitive assay and a direct assay. For both, we utilize 96-well microtiter plates and native low-density lipoprotein (LDL) for preparing the standard curve. A single monoclonal antibody, MB24, is used in the competitive assay. The direct assay involves use of two monoclonal antibodies, MB24 and MB47. These two antibodies bind to distinct, unrelated apo B epitopes expressed by all LDL particles, and both antibodies detect apo B in very low-density and intermediate-density lipoproteins as well as LDL. With the two-step competitive assay, which involves use of LDL-coated microtiter plates, the intra- and interassay reproducibility in plasma apo B measurements averaged 6% and 12%, respectively. In the one-step direct assay, which takes less than 2 h for completion, plasma samples and peroxidase-labeled MB24 are incubated simultaneously on MB47-coated microtiter wells. The amount of labeled MB24 bound to lipoproteins trapped by MB47 is proportional to apo B concentration. With the direct assay, intra- and interassay CVs averaged 7% and 12%, respectively. These assays are simple, reproducible, involve convenient incubation intervals, and do not require radioisotopes; thus they can be widely applied in clinical laboratories.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524903

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

1.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

2.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.

Authors:  W Palinski; S Hörkkö; E Miller; U P Steinbrecher; H C Powell; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 3.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

4.  Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.

Authors:  Anne P Beigneux; Kazuya Miyashita; Michael Ploug; Dirk J Blom; Masumi Ai; MacRae F Linton; Weerapan Khovidhunkit; Robert Dufour; Abhimanyu Garg; Maureen A McMahon; Clive R Pullinger; Norma P Sandoval; Xuchen Hu; Christopher M Allan; Mikael Larsson; Tetsuo Machida; Masami Murakami; Karen Reue; Peter Tontonoz; Ira J Goldberg; Philippe Moulin; Sybil Charrière; Loren G Fong; Katsuyuki Nakajima; Stephen G Young
Journal:  N Engl J Med       Date:  2017-04-05       Impact factor: 91.245

5.  Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.

Authors:  Jennifer M MacArthur; Joseph R Bishop; Kristin I Stanford; Lianchun Wang; André Bensadoun; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a).

Authors:  Ayelet Gonen; Xiaohong Yang; Calvin Yeang; Elena Alekseeva; Marlys Koschinsky; Joseph L Witztum; Michael Boffa; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

7.  Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance.

Authors:  Kristin I Stanford; Lianchun Wang; Jan Castagnola; Danyin Song; Joseph R Bishop; Jillian R Brown; Roger Lawrence; Xaiomei Bai; Hiroko Habuchi; Masakazu Tanaka; Wellington V Cardoso; Koji Kimata; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

8.  Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.

Authors:  S G Young; S T Hubl; R S Smith; S M Snyder; J F Terdiman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

9.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.